Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
Journal Title: Haematology International Journal - Year 2017, Vol 1, Issue 1
Abstract
1.1. Background: A significant survival prolongation was recently reported by adding idelalisib to rituximab (IR) compared with rituximab (R) in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). No direct data are available about the relative safety and effectiveness of IR versus other commonly used treatments. The economic impact of novel treatments for CLL is still unknown and no study ever attempted in assessing the benefit-for-cost of IR as compared with the several available treatment options. 1.2. Aim: To investigate the economic and clinical impact of IR in CLL 1.3. Objective: To understand the potential clinical and economic advantage of IR in CLL patients who failed one prior treatment line (i.e. refractory to or relapsed after prior treatment lines), as compared with immunotherapy and chemoimmunotherapy. 1.4. Methods: A treatment-sequence model was developed to estimate the incremental cost per QALY of IR versus R, bendamustine-rituximab (BR) and fludarabine cyclophosphamide-rituximab (FCR) in the second-line treatment setting (i.e. refractory to or relapsed after first-line therapy)in Italy. Tree Age 2015 software was used to simulate second-to-third line treatment sequences by a five-states Markov model: the model was run at monthly steps for 30years.Probabilities of progression were obtained from published randomized and phase II studies (Furman, et al. 2014, Awan, et al. 2014, Fisher, et al. 2011): data were adapted to a second-line setting according to a fixed hazard ratio of 1.4 between subsequent lines. The analysis was performed in the perspective of the Italian national health-care system. 1.5. Results: Base case analysis reported that IR improved quality-adjusted life expectancy by 1.91, 1.41 and 0.86 years as compared with R, BR and FCR. The incremental cost per quality-adjusted year (QALY) was €2,993, €16,045 and €28,045, respectively. The main drivers of the model were: time horizon, idelalisib unit cost and treatment duration. Deterministic and probabilistic sensitivity analyses showed that treatment with IR was cost-effective at conventional willingness-to-pay threshold (€40,000 per QALY). 1.6. Conclusion: Based in this model, IR is a cost-effective option for CLL patients who deserve a second-line treatment.
Authors and Affiliations
Monia Marchetti
Keywords
Related Articles
- EP ID EP291037
- DOI -
- Views 127
- Downloads 0
The Role of Uric Acid in Carbohydrate Metabolism among Hypertensive Individuals
The association between fasting blood glucose and insulin and serum uric acid levels in general population, as well as the positive association between serum uric acid levels and development of type 2 diabetes mellitus h...
Knowledge, Perception and Opinion of Health Workers on Bone Marrow Transplantation in Nigeria
1.1. Background: Bone marrow transplantation (BMT) or haematopoietic stem cell transplantation (HSCT) is a procedure used to cure haematopoietic malignancies, poorly functioning haematopoietic or immune system and geneti...
Survey of Pentazocine Addiction and Opioid Use in Adult Sickle Cell Anaemia Patients: The Perspective of Healthcare Providers
1.1. Background: Sickle cell anaemia (SCA) is characterized by episodes of bone paincreating a major role for analgesic therapy in the emergency management of this condition. Opioids, including pentazocine,is used in som...
Surface and Interacellular Targets of Acute Myeloid Leukemia Therapy Detectable at Leukemic Stem Cell level
For over 50 years investigators have considered a malignant stem cell as the potential origin of and a key therapeutic target for acute myeloid leukaemia (AML) and other forms of cancer [1]. Leukaemic stem cells (LSCs) h...
Iatrogenic Cushing’s Syndrome with Secondary Adrenal Suppression Misdiagnosed as Protease Inhibitor-Induced Lipodystrophy in an HIV Positive Patient: Case Report
1.1. Background: Ritonavir is a commonly prescribed protease inhibitor (PI) which is used in low doses to boost levels of other protease inhibitors pharmacokinetically. It is a potent inhibitor of hepatic cytochrome P450...